Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer
October 20 2016 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the appointment of Andy Hurley to the newly created
position of chief commercial officer, effective immediately. In
this role, Mr. Hurley will be responsible for leading Ocular’s
commercial organization, focusing on effective execution of
potential future product launches, brand development, and ongoing
commercialization strategies.
“Andy brings extensive commercial strategy and product launch
expertise as well as a proven ability to develop and lead
commercialization efforts globally,” said Amar Sawhney, Ph.D.,
President, Chief Executive Officer and Chairman of Ocular
Therapeutix. “Andy’s experience will be extremely valuable as we
continue to prepare for the potential launch of our lead product
candidate, DEXTENZA™, where our objective is to maximize product
uptake and revenue from the outset. If approved by the FDA, we
believe DEXTENZA would be the first extended release steroid
containing no preservatives available to ophthalmologists that
would provide the complete course of therapy with a single
placement.”
Mr. Hurley has over two decades of sales, marketing, market
access and commercial operations experience across the
pharmaceutical industry. Most recently, Mr. Hurley served as Vice
President, Sales and Marketing at Dyax Corporation prior to its
acquisition by Shire in January 2016. In this role, Mr. Hurley led
the strategic and tactical launch planning for the launch of
DX-2930, a product candidate under development for the treatment of
hereditary angioedema, or HAE. Prior to Dyax, Mr. Hurley held
several senior positions within Sunovion Pharmaceuticals, including
Vice President of Marketing and Vice President of Commercial
Operations. At Sunovion, he was responsible for leading all
marketing activities for its asthma franchise, including overall
strategic planning, life cycle strategy, advertising campaigns, and
market research. He also led commercial operations functions
including sales training, relationship marketing and sales
operations. Earlier in his career, Mr. Hurley held commercial
operations and sales roles at NitroMed and Forest Pharmaceuticals.
Mr. Hurley has also held various consulting roles, providing
commercial strategy development and tactical support to the biotech
industry.
“I am excited to join Ocular Therapeutix at such an important
juncture for the Company as it prepares for the potential
commercialization of DEXTENZA,” stated Mr. Hurley. “I look forward
to working with the world class team at Ocular to launch and
commercialize DEXTENZA as well as the Company’s additional
innovative, extended release product candidates across diverse
indications in ophthalmology.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel platform technology. Ocular Therapeutix
has submitted an NDA for post-surgical pain for its lead product
candidate, DEXTENZA™ (dexamethasone insert, extended release),
which is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis, and in Phase 2
clinical development for dry eye disease. OTX-TP (sustained release
travoprost) is in Phase 3 clinical development for glaucoma and
ocular hypertension. Ocular Therapeutix is also evaluating
sustained-release injectable drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
For additional information about the Company, please visit
www.ocutx.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company including the development and
regulatory status of the Company’s product candidates, such as the
Company’s expectations and plans regarding regulatory submissions
for and the timing and conduct of clinical trials of DEXTENZA™ for
post-surgical ocular inflammation and pain, including our
expectations regarding the NDA filed with the FDA, DEXTENZA for the
treatment of allergic conjunctivitis, DEXTENZA for dry eye disease
and OTX-TP for the treatment of glaucoma and ocular hypertension,
the potential utility of any of the Company’s product candidates,
potential commercialization of the Company’s product candidates,
the sufficiency of the Company’s cash resources and other
statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend", "goal," "may", "might," "plan,"
"predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors. Such forward-looking
statements involve substantial risks and uncertainties that could
cause the Company’s clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, those related to the
timing and costs involved in commercializing ReSure® Sealant or any
product candidate that receives regulatory approval, the initiation
and conduct of clinical trials, availability of data from clinical
trials and expectations for regulatory submissions and approvals,
the Company’s scientific approach and general development progress,
the availability or commercial potential of the Company’s product
candidates, the sufficiency of cash resources and need for
additional financing or other actions and other factors discussed
in the “Risk Factors” section contained in the Company’s quarterly
and annual reports on file with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161020005459/en/
InvestorsOcular Therapeutix, Inc.Brad SmithChief
Financial Officerbsmith@ocutx.comorBurns McClellan on behalf of
Ocular TherapeutixSteve Klass,
212-213-0006sklass@burnsmc.comorMediaOcular Therapeutix,
Inc.Scott CorningVice President of Sales and
Marketingscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024